Business Wire

DIABETES-CENTER-BERNE

Share
Diabetes Center Berne Launches Its First Open Innovation Challenge and Supports the Most Promising Ideas Submitted With Coaching, Expertise and a Total of 200,000 USD in Funding

In the last few years, diabetes technology has made enormous progress in improving the lives of people living with diabetes. However, there is still a great unmet need for innovative technology solutions that help ease the burden of diabetes and improve the lives of people who have it. One of these unmet needs is better glucose measurement. People with diabetes are asking for methods of glucose measurement that are more convenient, less invasive and more affordable. Hence why Diabetes Center Berne (DCB) is setting this challenge.

THE TOPIC
“Can your idea change glucose measurement forever?”

BACKGROUND
DCB is looking for innovators, co-creators, scientists and members of the diabetes community from around the world to join our open call for ideas and be part of an innovative community at the forefront of diabetes technology. Whether you are a start-up, a healthcare professional, a researcher or an individual, if you have an idea or insight into how to improve the lives of people living with diabetes, DCB wants to hear from you!

SUMBISSION DEADLINE
Ideas can be submitted up until 30 June 2021 via the sign-up page: dcb-innovation-challenge.com

ABOUT DCB
The Diabetes Center Berne Foundation is a private, independent Swiss foundation, established in 2017. It helps research projects and entrepreneurial ideas to grow. Based in Switzerland, Diabetes Center Berne provides projects around the world with expertise, access to clinical research facilities and its own laboratories and workspaces, as well as financial resources. It is located at the sitem on the Insel Campus in the Swiss capital Berne. DCB works in close scientific partnership with the Department of Diabetes, Endocrinology, Clinical Nutrition and Metabolism of Bern University Hospital (UDEM ), a university hospital with a stellar international reputation in the field of diabetes technology.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EV Group Strengthens Its European Presence With the Acquisition of Cornelius Polska22.1.2026 13:19:00 CET | Press release

Eigenmann & Veronelli Group (“EV Group”), a leading distributor and manufacturer of specialty chemicals and food ingredients, has signed an agreement to acquire the majority shareholding in Cornelius Polska. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122961168/en/ Photographed (left to right): Ludovico Balbo di Vinadio, Shareholder and Deputy Chairman, EV Group; Piotr Wasilewski, General Manager, Cornelius Polska Sp. z. o. o.; Cristina Colombo, Chief Financial Officer, EV Group; Dr Neville Prior, Group Chairman, Cornelius Group plc; Gabriele Bonomi, Chief Executive Officer, EV Group Established in Poland in 2007 and headquartered in Warsaw, Poland, Cornelius Polska is a well‑established distributor of specialty chemicals, serving as a key partner to international suppliers, and a broad and diverse customer base. With operations firmly rooted in Poland, the company is active in the beauty & personal care, food, and sev

Concept Medical Announces First Patient Enrollment in STARS DAPT Randomized Clinical Trial Evaluating Abluminus NP Polymer-Free DES22.1.2026 13:00:00 CET | Press release

Concept Medical Inc., a global pioneer in innovative drug delivery technology, is proud to announce the successful enrollment of the first patients in the STARS DAPT (ST-Segment Elevation Myocardial InfArction treated with a Polymer-Free Sirolimus-based NanocarrieR Eluting Stent and a P2Y12 inhibitor-based Single Antiplatelet Strategy after a Short Dual Antiplatelet Therapy versus conventional Dual AntiPlatelet Therapy) randomized controlled trial. This trial marks a significant milestone in evaluating the breakthrough technology of polymer free drug eluting stent (DES) for the treatment of STEMI patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121338054/en/ Concept Medical announces first patient enrollment in the STARS DAPT randomized clinical trial evaluating Abluminus™ NP polymer-free DES The first four patients were enrolled by (Professor Barbara Stähli and her team at the University Hospital of Zurich in Swi

SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing22.1.2026 12:00:00 CET | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request to continue its listing on the Nasdaq Stock Market, subject to stated conditions focused on timely completion of its financial audit and remediation of filing delinquencies. Under the Panel’s decision, SINOVAC must, on or before May 11, 2026, demonstrate compliance with Nasdaq Listing Rule 5250(c)(1) and Listing Rule 5250(c)(2) by completing filings of its annual report for the year ended December 31, 2024 on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of year 2025 on Form 6-K. As disclosed on January 4, 2026, the Company has engaged Zhonghua Certified Public Accountants LLP (“Zhonghua”) as its independent registered public accounting firm. SINOVAC is working diligently with Zhonghua to complete the required audit and t

Sisvel Launches Wi-Fi Multimode Patent Pool22.1.2026 12:00:00 CET | Press release

Ten patent owners establish licensing solution covering Wi-Fi 6 and Wi-Fi 7 standards Sisvel has launched a groundbreaking Wi-Fi Multimode patent pool offering access to standard essential patents owned by 10 Wi-Fi 6 and Wi-Fi 7 technology leaders. As the successor to Sisvel’s highly successful Wi-Fi 6 patent pool – which, over a three-year period, closed agreements with nearly 40 companies, including Acer, Netgear, Cisco and HP – the new programme offers an efficient way to access essential Wi-Fi rights for years to come. The 10 founding patent owners in the Wi-Fi Multimode programme are Huawei, KPN, Mitsubishi Electric, Orange, Panasonic, Philips, Aegis 11 SA (a Sisvel affiliate), SK Telecom, Wilus and ZTE. In addition, Sony Group Corporation has taken a licence under the Wi-Fi Multimode programme. This early agreement with a sophisticated and globally recognised Wi-Fi leader and implementer underlines the pool’s strong value proposition and the efforts made by Sisvel to engage with

Otto Group Enables AI-driven Intelligent Robot Coordination With the Digital Twin Developed by Roboverse Reply22.1.2026 11:52:00 CET | Press release

Reply [EXM, STAR: REY] is supporting the global retailer Otto Group in implementing a central, AI-driven virtual control system for intelligent robotic orchestration. Developed as part of a strategic collaboration between Otto Group, Reply, and NVIDIA, the "Robotic Coordination Layer" enables the training, simulation, and orchestration of autonomous mobile robots and stationary systems, accelerating delivery times and enhancing service levels This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122331989/en/ This initiative with the Otto Group and NVIDIA underscores Roboverse Reply’s role as an implementation partner for AI-powered robotics and Physical AI in logistics. At the centre is a high-fidelity digital twin, serving as a precise replica of the warehouse environment and accurately representing the positions, movements, and interactions of all robotic systems. Developed thanks to Roboverse Reply’s expertise in robotic int

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye